-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18

Benzinga·09/21/2026 16:30:57
Listen to the news
Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a In-Line and raises the price target from $16 to $18.